Close Menu
April 23, 2019
Sponsored by
N-of-One

AMP/ACMG/CAP Cancer Sequence Variant Guidelines: A Two-Year Status Report

Genome Webinar

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence. Upon the release of these guidelines, several laboratories and molecular diagnostic decision-support companies incorporated them into their reporting to give pathologists and treating oncologists a more consistent report format that clearly conveys the level of importance and evidence for each variant, enabling them to provide the most relevant treatment options for oncology patients.

In this webinar, Dr. Timothy Cannon, Medical Director for Gastrointestinal Cancers at Inova Medical Group, Dr. Marilyn Li, Vice Chief of the Division of Genomic Diagnostics at Children’s Hospital of Philadelphia, and Dr. Sheryl Elkin, CSO of N-of-One, a Qiagen company, discuss adoption of the guidelines in the field to date, what’s working, and any new challenges/opportunities that have come from the initial launch.

Attendees can expect to learn about some of the complexities that exist in incorporating the AMP guidelines into treatment strategies, as well as what might be on the horizon in industry standardization for levels of evidence.  

Sponsored by
Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Mar
30
Sponsored by
Menarini Silicon Biosystems

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.